Cargando…
Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19
We presented the clinical course and immune responses of a well-controlled HIV-positive patient with COVID-19. The clinical presentation and antibody production to SARS-CoV-2 were similar to other COVID-19 patients without HIV infection. Neutralizing antibody reached a plateau from 26th to 47th day...
Autores principales: | Liu, Wang-Da, Hung, Chien-Ching, Wang, Jann-Tay, Tsai, Ming-Jui, Kuo, Po-Hsien, Chao, Tai-Ling, Hsieh, Szu-Min, Sheng, Wang-Huei, Chen, Yee-Chun, Chang, Sui-Yuan, Chang, Shan-Chwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Formosan Medical Association. Published by Elsevier Taiwan LLC.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059939/ https://www.ncbi.nlm.nih.gov/pubmed/33933336 http://dx.doi.org/10.1016/j.jfma.2021.04.010 |
Ejemplares similares
-
Evolution of neutralizing antibodies and cross-activity against different variants of SARS-CoV-2 in patients recovering from COVID-19
por: Liu, Wang-Da, et al.
Publicado: (2022) -
Prolonged virus shedding even after seroconversion in a patient with COVID-19
por: Liu, Wang-Da, et al.
Publicado: (2020) -
Experience of the use of hydroxychloroquine on patients with COVID-19: A perspective on viral load and cytokine kinetics
por: Liu, Wang-Da, et al.
Publicado: (2021) -
Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure
por: Hsieh, Szu-Min, et al.
Publicado: (2009) -
Accelerated progression of pulmonary tuberculosis in a COVID-19 patient after corticosteroid treatment
por: Liu, Wang-Da, et al.
Publicado: (2022)